Policy report outlines 21 draft proposals for expanding agency disclosure while protecting trade secrets, highlighting ongoing regulatory reform.
The FDA recently released a report from its Transparency Task Force containing 21 draft proposals for expanding the disclosure of information by the agency while maintaining confidentiality for trade secrets and individually identifiable patient information. Afia Asamoah and Dr. Joshua Sharfstein from the FDA discuss the transparency initiative.
No takes yet. Share an insight, caveat, or question.
Asamoah et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: